YELLOWSTONE SCIENTIFIC INSTRUMENTS

Medtech

Point-of-care diagnostic device using surface-enhanced Raman spectroscopy (SERS) and proprietary nanoparticle chemistry to detect medication adherence biomarkers in urine samples

Grants
$1.9M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Device for Noninvasive Monitoring of Multiple Biomarkers for Drug Abuse$150,024
Federal grantDepartment of Health and Human Services · Phase II · Monitor for Multiple Biomarkers for Detection of Alcohol Consumption$459,740
Federal grantDepartment of Health and Human Services · Phase II · Monitor for Multiple Biomarkers for Detection of Alcohol Consumption$442,680
Federal grantDepartment of Health and Human Services · Phase I · Adherence Monitor for Substance Use Disorder Treatment$149,800
Federal grantDepartment of Health and Human Services · Phase II · Adherence Monitor for Substance Use Disorder Treatment$337,992
Federal grantDepartment of Health and Human Services · Phase II · Adherence Monitor for Substance Use Disorder Treatment$397,991
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2121RESUSCITATION INNOVATIONS LLC——
2122XANDEM TECHNOLOGY, LLC——
2123MOBIUS BIOTECH LLC——
2124YELLOWSTONE SCIENTIFIC INSTRUMENTS——
2125DELTAMED LLC——
2126CERETYPE NEUROMEDICINE IN——
2127Hays, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.